{
  "abstract": "In the KARE trial, 96 adults with severe alcohol use disorder, abstinent following detoxification, were randomised in a 2×2 factorial design to 3 weekly infusions of ketamine (0.8 mg/kg) or saline, each combined with mindfulness-based psychological support (PS) or alcohol psychoeducation (PE). We re-expressed the trial data on endpoints acceptable to regulators and compared the most and least intensive arms. Across pooled weeks 17–24, ketamine plus PS gave 78.5% versus 57.8% days abstinent (difference, 20.7 percentage points; P = .032); adjusted for baseline, the difference at weeks 21–24 was 26.9 percentage points (P = .011). At weeks 21–24, 50.0% versus 26.1% had no heavy drinking days (P = .127). Relative reductions in heavy drinking days were 55% in KARE, against 25%, −17%, 46% and 35% reported for naltrexone, exenatide, semaglutide and pemvidutide. These post hoc differences, measured 4 to 6 months after a 4 week course ended, are of magnitude similar to agents requiring continuous administration.",
  "abstract_shown": true,
  "affiliations": [
    "University of Exeter"
  ],
  "article_type": "PUBLISHAHEADOFPRINT",
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "C. J. Morgan"
    },
    {
      "name": "D. J. Nutt"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/dxw7vk9g57ch6.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.09.26.26363761",
  "fulltext_url": "https://www.medrxiv.org/content/10.64898/2026.09.26.26363761v1.full",
  "id": "dxw7vk9g57ch6",
  "issns": [],
  "landing_url": "https://www.medrxiv.org/content/10.64898/2026.09.26.26363761v1",
  "language": null,
  "licence": "PDM-1.0",
  "licence_label": "Public domain",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/publicdomain/mark/1.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "medrxiv",
      "addiction medicine"
    ],
    [
      "openalex",
      "2713|Substance Abuse Treatment and Outcomes"
    ]
  ],
  "openalex": "W7214683046",
  "pdf_url": "https://www.medrxiv.org/content/10.64898/2026.09.26.26363761v1.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-26",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/dxw7vk9g57ch6.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:33Z",
      "native_id": "10.64898/2026.09.26.26363761",
      "source": "medrxiv",
      "url": "https://www.medrxiv.org/content/10.64898/2026.09.26.26363761v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "medrxiv:addiction medicine",
      "subfield": "psychiatry"
    }
  ],
  "title": "No Heavy Drinking Days and Percentage of Days Abstinent in a Randomized Trial of Adjunctive Ketamine for Alcohol Use Disorder: Secondary Analysis of the KARE Trial",
  "title_text": "No Heavy Drinking Days and Percentage of Days Abstinent in a Randomized Trial of Adjunctive Ketamine for Alcohol Use Disorder: Secondary Analysis of the KARE Trial",
  "type": "preprint",
  "updated_at": "2026-10-30T12:19:33Z",
  "url": "https://research.draconitic.com/paper/dxw7vk9g57ch6",
  "venue": "medRxiv",
  "versions": []
}